Patents Assigned to Janssen Sciences Ireland Unlimited Company
  • GDF15 fusion proteins and uses thereof
    Patent number: 11208464
    Abstract: Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 28, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Anthony Armstrong, Judith Ann Connor, Jennifer Furman, Chichi Huang, Michael J. Hunter, Xiefan Lin-Schmidt, Serena Nelson, Shamina M. Rangwala, Shannon Mullican, Jose Antonio Chavez
  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 11129834
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: September 28, 2021
    Assignees: Novira Therapeutics, Inc., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • Aryl substituted pyrimidines for use in influenza virus infection
    Patent number: 11117887
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 14, 2021
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Tim Hugo Maria Jonckers, David Craig McGowan, Jérôme Émile Georges Guillemont, Werner Constant J Embrechts, Guillaume Jean Maurice Mercey, Christophe Francis Robert Nestor Buyck, Wendy Mia Albert Balemans, Pierre Jean-Marie Bernard Raboisson
  • Purine derivatives for the treatment of viral infections
    Patent number: 11104678
    Abstract: The present invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: August 31, 2021
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Jean-François Bonfanti, Frédéric Marc Maurice Doublet, Werner Embrechts, Jérôme Michel Claude Fortin, David Craig McGowan, Pierre Jean-Marie Bernard Raboisson
  • Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
    Patent number: 11096931
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 24, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Stefaan Julien Last, Bart Rudolf Romanie Kesteleyn, Sandrine Céline Grosse, Tim Hugo Maria Jonckers, Jan Martin Berke, Geerwin Yvonne Paul Haché, Edgar Jacoby, Carolina Martinez Lamenca, Morgan Charles R. Lecomte, Abdellah Tahri, Sarah Sauviller, Karen Maria Vergauwen
  • Use of a HIV derived accessory protein for the reactivation of latent HIV
    Patent number: 11098085
    Abstract: The present invention concerns the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: August 24, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventor: Daniel Boden
  • RSV antiviral pyrazolo- and triazolo-pyrimidine compounds
    Patent number: 11084826
    Abstract: The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 10, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: David Francis Alain Lançois, Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Dirk André Emmy Roymans, Boris Rogovoy, Vadim Bichko, Delphine Yvonne Raymonde Lardeau, Antoine Benjamin Michaut, Anil Koul
  • Dispersible compositions
    Patent number: 11065198
    Abstract: The present invention is concerned with dispersible compositions comprising rilpivirine or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. Such compositions are useful in the treatment of HIV infection and their dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: July 20, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Harshad Patankar, Nicolaas Martha Felix Goyvaerts, Gopal Rajan Ranga Rajan
  • Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
    Patent number: 11053235
    Abstract: The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Gang Deng, Yimin Jiang, Qian Liu, Chao Liang, Zhao-Kui Wan, Wing Shun Cheung, Zhanling Cheng, Yanping Xu
  • Dihydropyranopyrimidines for the treatment of viral infections
    Patent number: 11053256
    Abstract: This invention relates to dihydropyranopynmidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Jérôme Émile Georges Guillemont, David Craig McGowan, Werner Constant Johan Embrechts, Ludwig Paul Cooymans, Laurent Calmus
  • Capsid assembly modulator dosing regimen
    Patent number: 10973801
    Abstract: The present disclosure is directed to methods of using a capsid assembly inhibitor for the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Koen Vandyck, Oliver Lenz, Claire Elisabeth Balmain, Jan Snoeys, Joris Jozef Vandenbossche, Dominique Josiane W. Verstraete, Jeysen Zivan Yogaratnam, Maria Jansens, Frederic Van Dycke
  • Pyrimidine prodrugs for the treatment of viral infections and further diseases
    Patent number: 10968184
    Abstract: This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Jérôme Émile Georges Guillemont, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, David Craig McGowan, Werner Constant Johan Embrechts, Bart Henri Theresia Stoops, Florence Marie Herschke, Jacques Armand Henri Bollekens, Laurent Jacques Emile Calmus
  • Long term treatment of HIV-infection with TMC278
    Patent number: 10953009
    Abstract: This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered intermittently at a time interval of at least one week.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: March 23, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Lieven Elvire Colette Baert, Guenter Kraus, Gerben Albert Eleutherius Van ′T Klooster
  • Pyridone derivatives for the treatment of viral infections and further diseases
    Patent number: 10865193
    Abstract: This invention relates to pyridone derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: December 15, 2020
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson
  • Pseudopolymorphic forms of a HIV protease inhibitor
    Patent number: 10858369
    Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: December 8, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Hans Wim Pieter Vermeersch, Daniel Joseph Christiaan Thone, Luc Donne Marie-Louise Janssens, Piet Tom Bert Paul Wigerinck
  • Macrocyclic deaza-purinones for the treatment of viral infections
    Patent number: 10829494
    Abstract: This invention relates to macrocyclic deaza-purinones derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: November 10, 2020
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Jean-François Bonfanti, Jérôme Michel Claude Fortin, Philippe Muller, Frédéric Marc Maurice Doublet, Pierre Jean-Marie Bernard Raboisson, Eric Pierre Alexandre Arnoult
  • Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
    Patent number: 10822347
    Abstract: This invention relates to thieno[3,2-d]pyrimidines derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: November 3, 2020
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson
  • Macrocyclic purines for the treatment of viral infections
    Patent number: 10822349
    Abstract: This invention relates macrocyclic purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: November 3, 2020
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Jean-François Bonfanti, Jérôme Michel Claude Fortin, Frédéric Marc Maurice Doublet, Pierre Jean-Marie Bernard Raboisson, Eric Pierre Alexandre Arnoult
  • HETEROCYCLIC COMPOUNDS AS ANTIBACTERIALS
    Publication number: 20200308169
    Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 1, 2020
    Applicant: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: Jérôme Émile Georges Guillemont, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
    Patent number: 10781216
    Abstract: This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 22, 2020
    Assignee: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
    Inventors: David Craig McGowan, Serge Maria Aloysius Pieters, Stefaan Julien Last, Werner Embrechts, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson